Insulin resistance and adiponectin levels in psoriasis patients;Ocena insulinooporności oraz stȩżenia adiponektyny u chorych na łuszczycȩ zwyczajna̧

Postepy Dermatologii i Alergologii

Volumn 27, Issue 6, 2010, Pages 451-455

  Janusz, Iwo ^a   Lewandowski, Krzysztof ^b   Lukamowicz, Jolanta ^c   Świa̧tkowska, Ewa ^c   Narbutt, Joanna ^d   Zalewska Janowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Klinika Endokrynologii I Chorob Metabolicznych Instytutu Centrum Zdrowia Matki Polki W odzi   (Poland)

^c POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^d Klinika Dermatologii i Wenerologii Uniwersytetu Medycznego w odzi   (Poland)

Author keywords

Adiponectin; Insulin resistance; Polymetabolic syndrome; Psoriasis

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE DURATION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; RISK FACTOR;

EID: 78651362598     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20.
2. Capon F, Munro M, Barker J, et al. Searching for the major histocompatibility complex psoriasis susceptibility gene. J Incest Dermatol 2002; 118: 745-51.
3. Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8.
4. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-7.
5. Walters M. Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol 2005; 153: 706-14.
6. Bos JD, de Rie MA, Teunissen MB, et al. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005; 152: 1098-107.
7. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155: 145-58.
8. Gearing AJ, Fincham NJ, Bird CR, et al. Cytokines in skin lesions of psoriasis. Cytokine 1990; 2: 68-75.
9. Gröne A. Keratinocytes and cytokines. Vet Immunol Immunopathol 2002; 88: 1-12.
10. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73. (Pubitemid 46934281)
11. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
12. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-8.
13. Hadas E, Bożek A, Jarza̧b J. Wpływ fototerapii na wybrane wskaźniki profilu lipidowego u chorych na łuszczycȩ zwykła̧ z uwzglȩdnieniem nasilenia procesu chorobowego. Post Dermatol Alergol 2007; 24: 215-23. (Pubitemid 350200451)
14. Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000; 66: 348-52.
15. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009; 129: 1601-3.
16. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Dermatol 2009; 145: 379-82.
17. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
18. McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 1973; 26: 912.
19. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99: 469-75.
20. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-6.
21. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298-304.
22. Alexander E, Pinto J, Pal GS, et al. Disease concomitance in psoriasis: A clinical study of 61 cases. Indian J Dermatol Venereol Leprol 2001; 67: 66-8.
23. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-30.
24. Ayala F, Ayala F. Clinical aspects and comorbilities of psoriasis. J Rheumatol Suppl 2009; 83: 19-20.
25. López-Candales A. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. J Med 2001; 32: 283-300. (Pubitemid 34464466)
26. Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol 2000; 16: 779-89.
27. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-6.
28. Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23: 1311-5.
29. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21.
30. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
31. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
32. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-5.
33. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-9.